Last June, scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments.
What's more, years of animal studies and early human clinical trials show that this tumor-targeting alkylphosphocholine (APC) molecule can deliver two types of "payloads" directly to cancer cells: a radioactive or fluorescent imaging label, or a radioactive medicine that binds and kills cancer cells. This series of images shows how the APC molecule targets and illuminates cancer cells.